124 related articles for article (PubMed ID: 38667935)
1. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
2. Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.
Chiu CY; John TM; Matsuo T; Wurster S; Hicklen RS; Khattak RR; Ariza-Heredia EJ; Bose P; Kontoyiannis DP
J Fungi (Basel); 2024 Mar; 10(4):. PubMed ID: 38667935
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti F; Lou Y; Chevli M; Abraham P
Future Oncol; 2023 Nov; ():. PubMed ID: 37991002
[TBL] [Abstract][Full Text] [Related]
6. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
Prakash K; Richman D
BMC Infect Dis; 2019 Mar; 19(1):287. PubMed ID: 30917797
[TBL] [Abstract][Full Text] [Related]
7. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
8. Impact of climate change and natural disasters on fungal infections.
Seidel D; Wurster S; Jenks JD; Sati H; Gangneux JP; Egger M; Alastruey-Izquierdo A; Ford NP; Chowdhary A; Sprute R; Cornely O; Thompson GR; Hoenigl M; Kontoyiannis DP
Lancet Microbe; 2024 Jun; 5(6):e594-e605. PubMed ID: 38518791
[TBL] [Abstract][Full Text] [Related]
9. Tracing histoplasmosis genomic epidemiology and species occurrence across the USA.
Tenório BG; Kollath DR; Gade L; Litvintseva AP; Chiller T; Jenness JS; Stajich JE; Matute DR; Hanzlicek AS; Barker BM; Teixeira MM
Emerg Microbes Infect; 2024 Dec; 13(1):2315960. PubMed ID: 38465644
[No Abstract] [Full Text] [Related]
10. Detection of
Granger D; Streck NT; Theel ES
J Clin Microbiol; 2024 Jan; 62(1):e0121323. PubMed ID: 38099670
[No Abstract] [Full Text] [Related]
11. Infection of bats with Histoplasma species.
Gugnani HC; Denning DW
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37553137
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.
Wurster S; Watowich SS; Kontoyiannis DP
Front Immunol; 2022; 13():1018202. PubMed ID: 36389687
[TBL] [Abstract][Full Text] [Related]
13. The Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era.
Mazi PB; Sahrmann JM; Olsen MA; Coler-Reilly A; Rauseo AM; Pullen M; Zuniga-Moya JC; Powderly WG; Spec A
Clin Infect Dis; 2023 Apr; 76(7):1295-1301. PubMed ID: 36366776
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
